Deborah Ricci

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer

Andrés Poveda, Stanley B. Kaye, Robert McCormack et al. · Gynecologic Oncology · 2011 · 176 citations

Medicine, Pathology, Gynecology +8

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii A. Osmanov et al. · Blood · 2015 · 135 citations · Full text

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

George Mulligan, David I. Lichter, Alessandra Di Bacco et al. · Blood · 2013 · 115 citations · Full text

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

Dana E. Rathkopf, Matthew R. Smith, Charles J. Ryan et al. · Annals of Oncology · 2017 · 98 citations · Full text

Urology, Oncology, Medicine +5

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Matthew R. Smith, Shahneen Sandhu, William Kevin Kelly et al. · Annals of Oncology · 2019 · 94 citations

Urology, Genitourinary Cancer, Medicine +6